Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: Comment on the article by Yoo

被引:3
作者
Daoussis, Dimitrios [1 ]
Andonopoulos, Andrew P. [1 ]
机构
[1] Univ Patras, Sch Med, Patras Univ Hosp, Div Rheumatol,Dept Internal Med, Patras 26504, Greece
关键词
Systemic sclerosis; Scleroderma; Rituximab; Interstitial lung disease; B cells; Fibrosis; Skin thickening; Rheumatic diseases;
D O I
10.1007/s00296-010-1485-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several lines of evidence from basic research indicate that B cells may contribute to the pathogenesis of systemic sclerosis. Clinical studies as well have provided preliminary data pointing to the direction that B-cell depletion with rituximab might be a therapeutic option for patients with this debilitating disease.
引用
收藏
页码:841 / 842
页数:2
相关论文
共 5 条
[1]  
Daoussis D, 2009, SEMIN ARTHRITIS RHEU
[2]   Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study [J].
Daoussis, Dimitrios ;
Liossis, Stamatis-Nick C. ;
Tsamandas, Athanassios C. ;
Kalogeropoulou, Christina ;
Kazantzi, Alexandra ;
Sirinian, Chaido ;
Karampetsou, Maria ;
Yiannopoulos, Georgios ;
Andonopoulos, Andrew P. .
RHEUMATOLOGY, 2010, 49 (02) :271-280
[3]   B Cell Depletion With Rituximab in Patients With Diffuse Cutaneous Systemic Sclerosis [J].
Lafyatis, Robert ;
Kissin, Eugene ;
York, Michael ;
Farina, Giuseppina ;
Viger, Kerry ;
Fritzler, Marvin J. ;
Merkel, Peter A. ;
Simms, Robert W. .
ARTHRITIS AND RHEUMATISM, 2009, 60 (02) :578-583
[4]   Rituximab: a potential therapeutic advance in scleroderma What is the evidence? [J].
Simms, Robert W. ;
Lafyatis, Robert .
RHEUMATOLOGY, 2010, 49 (02) :201-202
[5]   Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study [J].
Smith, V. ;
Van Praet, J. T. ;
Vandooren, B. ;
Van der Cruyssen, B. ;
Naeyaert, J-M ;
Decuman, S. ;
Elewaut, D. ;
De Keyser, F. .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (01) :193-197